800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors
Thomas Eigentler, Lucie Heinzerling, Jürgen Krauss, Carsten Weishaupt, Peter Mohr, Sebastian Ochsenreither, Patrick Terheyden, Juan Martin-Liberal, Marc Oliva, Céleste Lebbe, Michael Fluck, Peter Brossart, Jose Manuel Trigo Perez, Franz-Georg Bauernfeind, Sarah-Katharina Kays, Tobias Seibel, Oliver Schönborn-Kellenberger, Claudia Stosnach, Angelika Daehling, Beate Schmitt-Bormann, Ulrike Gnad-Vogt
Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A849; DOI: 10.1136/jitc-2020-SITC2020.0800